First Turn Management, LLC
13F Reported Value
ⓘ$934.7M
Holdings
31
Latest Filing
2026-06-30
Filing Quarter
Q2 2026
Portfolio Overview
First Turn Management, LLC disclosed 31 positions worth $934.7M in its Form 13F-HR for Q2 2026, led by $RVMD (Revolution Medicines, Inc.) at 8.3% of the equity portfolio, followed by $ABVX and $AXSM. During the quarter the fund opened 5 new positions and exited 7 — including a new stake in $PCVX and a full exit from $IDYA. The portfolio is most concentrated in Healthcare (100.0% of disclosed assets). All figures are sourced directly from First Turn Management, LLC’s Form 13F-HR filing with the SEC under CIK 1993440.
AI Fund Analysis
ConcentratingSector Allocation
AUM History
Top Equity Holdings by Value
Quarterly Activity — Q2 2026
Click any card to unlockTop Holdings
- —
Quality
$77.8M415,307 sh - —
Quality
$65.3M489,889 sh - 40.8#2,087
Quality
$53.5M218,415 sh - —
Quality
$48.4M954,360 sh - 36.9
Quality
$47.2M633,364 sh - —
Quality
$47.1M1,331,066 sh - 71.3
Quality
$46.0M84,932 sh - 28.1
Quality
$44.9M527,412 sh - 24.0
Quality
$36.2M600,200 sh - —
Quality
$34.4M329,101 sh
| Company | Quality | Value | Shares |
|---|---|---|---|
 Revolution Medicines, Inc.$RVMD | — | $77.8M | 415,307 |
 Abivax S.A.$ABVX | — | $65.3M | 489,889 |
 Axsome Therapeutics, Inc.$AXSM | 40.8#2,087 | $53.5M | 218,415 |
 Enliven Therapeutics, Inc.$ELVN | — | $48.4M | 954,360 |
 BridgeBio Pharma, Inc.$BBIO | 36.9 | $47.2M | 633,364 |
 Roivant Sciences Ltd.$ROIV | — | $47.1M | 1,331,066 |
 UNITED THERAPEUTICS Corp$UTHR | 71.3 | $46.0M | 84,932 |
 CYTOKINETICS INC$CYTK | 28.1 | $44.9M | 527,412 |
 Xenon Pharmaceuticals Inc.$XENE | 24.0 | $36.2M | 600,200 |
 Celcuity Inc.$CELC | — | $34.4M | 329,101 |
Unlock AI quality scores for every holding
32-signal composite ranking on each of First Turn Management, LLC's 31 positions.
Showing top 10 of 31 holdings.
Sector Allocation
Healthcare
$934.7M
Full Holdings — First Turn Management, LLC (Q2 2026)
All 31 disclosed positions from the latest Form 13F-HR, with quarter-over-quarter share changes and 13F Pro quality scores. Sourced from SEC EDGAR.
| # | Ticker | Company | Value | Weight | QoQ | Quality |
|---|---|---|---|---|---|---|
| 1 | $RVMD | Revolution Medicines, Inc. | $77.8M | 8.3% | -11% | — |
| 2 | $ABVX | Abivax S.A. | $65.3M | 7.0% | +5% | — |
| 3 | $AXSM | Axsome Therapeutics, Inc. | $53.5M | 5.7% | +16% | 40.8 |
| 4 | $ELVN | Enliven Therapeutics, Inc. | $48.4M | 5.2% | +53% | — |
| 5 | $BBIO | BridgeBio Pharma, Inc. | $47.2M | 5.0% | -9% | 36.9 |
| 6 | $ROIV | Roivant Sciences Ltd. | $47.1M | 5.0% | +12% | — |
| 7 | $UTHR | UNITED THERAPEUTICS Corp | $46.0M | 4.9% | -19% | 71.3 |
| 8 | $CYTK | CYTOKINETICS INC | $44.9M | 4.8% | +86% | 28.1 |
| 9 | $XENE | Xenon Pharmaceuticals Inc. | $36.2M | 3.9% | -24% | 24 |
| 10 | $CELC | Celcuity Inc. | $34.4M | 3.7% | +56% | — |
| 11 |  $VRDN | Viridian Therapeutics, Inc.\DE | $30.7M | 3.3% | +83% | 27.2 |
| 12 |  $INSM | INSMED Inc | $28.1M | 3.0% | +6% | 39.4 |
| 13 |  $QURE | uniQure N.V. | $28.0M | 3.0% | -1% | — |
| 14 |  $ASND | Ascendis Pharma A/S | $28.0M | 3.0% | +37% | 44.8 |
| 15 |  $PRAX | Praxis Precision Medicines, Inc. | $28.0M | 3.0% | +97% | — |
| 16 |  $DNTH | Dianthus Therapeutics, Inc. /DE/ | $27.9M | 3.0% | +29% | 22.6 |
| 17 |  $PCVX | Vaxcyte, Inc. | $25.8M | 2.8% | NEW | — |
| 18 |  $MIRM | Mirum Pharmaceuticals, Inc. | $25.5M | 2.7% | -46% | 35 |
| 19 |  $PVLA | PALVELLA THERAPEUTICS, INC. | $23.9M | 2.6% | +6% | — |
| 20 |  $COGT | Cogent Biosciences, Inc. | $23.3M | 2.5% | -36% | — |
| 21 |  $ERAS | Erasca, Inc. | $22.4M | 2.4% | +41% | — |
| 22 |  $ORIC | Oric Pharmaceuticals, Inc. | $21.8M | 2.3% | +0% | — |
| 23 |  $NAMS | NewAmsterdam Pharma Co N.V. | $19.7M | 2.1% | +4% | — |
| 24 |  $APGE | Apogee Therapeutics, Inc. | $18.4M | 2.0% | -73% | — |
| 25 |  $RYTM | RHYTHM PHARMACEUTICALS, INC. | $17.1M | 1.8% | NEW | 33.9 |
| 26 |  $INBX | Inhibrx Biosciences, Inc. | $15.6M | 1.7% | NEW | 30 |
| 27 |  $SRRK | Scholar Rock Holding Corp | $14.9M | 1.6% | -39% | — |
| 28 |  $ORKA | Oruka Therapeutics, Inc. | $14.8M | 1.6% | NEW | — |
| 29 |  $KYMR | Kymera Therapeutics, Inc. | $11.8M | 1.3% | -60% | 28.4 |
| 30 |  $SION | Sionna Therapeutics, Inc. | $4.9M | 0.5% | NEW | — |
| 31 |  $NUVL | Nuvalent, Inc. | $3.2M | 0.3% | -93% | — |
New Positions (5)
Browse Top Institutional Investors
13F Pro tracks 8,700+ institutional investors filing 13F reports with the SEC.
to search all 8,700+ institutional filers.
Available Analysis
13F Pro tracks comprehensive institutional data for First Turn Management, LLC including:
Track First Turn Management, LLC's Full Portfolio
See every holding, quarter-over-quarter changes, sector allocation, and accumulation patterns for First Turn Management, LLC and 8,700+ other institutional investors.
Free tier includes full 13F search and fund profiles. Pro starts at $6.67/mo (billed annually).
AI-Powered Hedge Fund Analysis: First Turn Management, LLC
13F Pro is an AI hedge fund tracker and stock research platform. For First Turn Management, LLC (SEC CIK: 1993440), the platform ingests every quarterly Form 13F filing and applies AI-powered analysis on top — 10 specialized AI analysts (value, growth, momentum, macro, activist, and more) debate the fund's top positions and publish AI-generated analysis with cited SEC sources.
Every holding in First Turn Management, LLC's portfolio is scored on a 32-signal AI quality ranking (ROIC, FCF margin, revenue growth, institutional flow, earnings quality, shareholder dilution, and more). Track accumulation and distribution quarter over quarter, identify conviction positions, and see AI stock analysis for each position — alongside 8,700+ other institutional filers and 2,800+ AI-ranked companies.